Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi.
Margiotta-Casaluci G, Bigliardi S, Cocito F, Meli E, Petrucci L, Nicolosi M, Annibali O, Boccomini C, Bozzoli V, Castellino A, Cattina F, Cenfra N, Ciavarella S, Kovalchuk S, Rotondo F, Fama A, Olivieri J, Zaja F. Margiotta-Casaluci G, et al. Among authors: meli e. Front Oncol. 2023 Mar 10;13:1120967. doi: 10.3389/fonc.2023.1120967. eCollection 2023. Front Oncol. 2023. PMID: 36969038 Free PMC article.
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
Rusconi C, Anastasia A, Chiarenza A, Marcheselli L, Cavallo F, Rattotti S, Botto B, Ferrari A, Nassi L, Pagani C, Meli E, Arcaini L, Federico M, Rossi G; Fondazione Italiana Linfomi (FIL). Rusconi C, et al. Among authors: meli e. Br J Haematol. 2019 May;185(4):713-717. doi: 10.1111/bjh.15816. Epub 2019 Feb 21. Br J Haematol. 2019. PMID: 30793297 Free article.
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Gotti M, Sciarra R, Pulsoni A, Merli F, Luminari S, Zerbi C, Trentin L, Re A, Rusconi C, Viviani S, Rossi A, Cocito F, Botto B, Meli E, Pinto A, Dogliotti I, Gini G, Puccini B, Ricci F, Nassi L, Fabbri A, Liberati AM, Merli M, Filippi AR, Bonfichi M, Zoboli V, Tartaglia G, Annechini G, D'Elia GM, Del Giudice I, Alvarez I, Visentin A, Pravato S, Dalceggio D, Pagani C, Ferrari S, Cristinelli C, Lazic T, Ferretti VV, Ricardi U, Arcaini L. Gotti M, et al. Among authors: meli e. Hemasphere. 2023 Apr 4;7(4):e837. doi: 10.1097/HS9.0000000000000837. eCollection 2023 Apr. Hemasphere. 2023. PMID: 37034003 Free PMC article.
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments.
Bari A, Marcheselli R, Sacchi S, Re A, Pagani C, Tucci A, Botto B, Vitolo U, Molinari AL, Puccini B, Pulsoni A, Santoro A, Tani M, Nassi L, Meli E, Pavone V, Bonfichi M, Evangelista A, Gioia D, Levis A, Zinzani P; Fondazione Italiana Linfomi (Onlus). Bari A, et al. Among authors: meli e. Ann Hematol. 2020 Feb;99(2):277-282. doi: 10.1007/s00277-019-03893-7. Epub 2019 Dec 23. Ann Hematol. 2020. PMID: 31872362 Free PMC article. Clinical Trial.
Management of vaccinations in patients with non-Hodgkin lymphoma.
Merli M, Costantini A, Tafuri S, Bavaro DF, Minoia C, Meli E, Luminari S, Gini G. Merli M, et al. Among authors: meli e. Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19422. Online ahead of print. Br J Haematol. 2024. PMID: 38532527 Review.
Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience.
Zilioli VR, Muzi C, Minga P, Codega P, Crucitti L, Meli E, Esposito A, Panico C, Rusconi C, Cairoli R. Zilioli VR, et al. Among authors: meli e. Int J Hematol Oncol. 2020 Feb 28;9(1):IJH23. doi: 10.2217/ijh-2020-0001. Int J Hematol Oncol. 2020. PMID: 32382409 Free PMC article.
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Zinzani PL, Rodgers T, Marino D, Frezzato M, Barbui AM, Castellino C, Meli E, Fowler NH, Salles G, Feinberg B, Kurukulasuriya NC, Tillmanns S, Parche S, Dey D, Fingerle-Rowson G, Ambarkhane S, Winderlich M, Nowakowski GS. Zinzani PL, et al. Among authors: meli e. Clin Cancer Res. 2021 Nov 15;27(22):6124-6134. doi: 10.1158/1078-0432.CCR-21-1471. Epub 2021 Aug 25. Clin Cancer Res. 2021. PMID: 34433649 Free PMC article.
Correction to: The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of pet-guided treatments.
Bari A, Marcheselli R, Sacchi S, Re A, Pagani C, Tucci A, Botto B, Vitolo U, Molinari AL, Puccini B, Pulsoni A, Santoro A, Tani M, Nassi L, Meli E, Pavone V, Bonfichi M, Evangelista A, Gioia D, Levis A, Zinzani P; Fondazione Italiana Linfomi (Onlus). Bari A, et al. Among authors: meli e. Ann Hematol. 2021 Jan;100(1):303-304. doi: 10.1007/s00277-020-04344-4. Ann Hematol. 2021. PMID: 33219839 Free PMC article. No abstract available.
46 results